{
  "main_header": {
    "sid": 1002696,
    "name": "Eiko Lifescience",
    "stock_name": "Eiko Lifescience",
    "full_name": "Eiko Lifesciences Ltd",
    "name_url": "stocks-analysis/eiko-lifescience",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "50.10",
    "chg": 0.94,
    "chgp": "1.91%",
    "dir": 1,
    "prev_price": "49.16",
    "mcapval": "72.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 540204,
    "symbol": "",
    "ind_name": "Specialty Chemicals",
    "ind_code": 5,
    "indexname": "India SENSEX",
    "isin": "INE666Q01016",
    "curr_date": "Aug 11",
    "curr_time": "",
    "bse_nse_vol": "2.72 k",
    "exc_status": "Active",
    "traded_date": "Aug 11, 2026",
    "traded_date_str": "2026 08 11",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://marketsmojo.motilaloswal.com/MOSL-Landingstocks-analysis/eiko-lifescience-1002696-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [],
    "total": 7,
    "sid": "1002696",
    "stock_news_url": "https://marketsmojo.motilaloswal.com/news/eiko-lifesciences-1002696"
  },
  "announcements": [
    {
      "caption": "Board Meeting Intimation for Meeting Scheduled To Be Held On 12Th August 2026",
      "datetime": "07-Aug-2026",
      "details": "Eiko Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 inter alia to consider and approve The Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended on 30th June 2026 in accordance with Regulation 33 of the SEBI Listing Regulation",
      "source": "BSE"
    },
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "13-Jul-2026",
      "details": "Certificate under Regulation 74(5) of SEBI (DP) Regulations 2018 for the quarter ended 30th June 2026",
      "source": "BSE"
    },
    {
      "caption": "Closure of Trading Window",
      "datetime": "24-Jun-2026",
      "details": "Trading Window shall remain closed for designated persons and their immediate relatives from Wednesday 01st July 2026 till 48 hours after the date of Board Meeting wherein inter-alia the approval of Un-Audited Standalone and Consolidated Financial Results for the quarter ended 30th June 2026 would be considered by the Board.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "",
      "data": [
        {
          "title": "BOARD MEETING",
          "txt": "12 Aug 2026"
        }
      ]
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Eiko Lifesciences Ltd has declared <strong>2%</strong> dividend, ex-date: 20 Sep 17",
          "dt": "2017-09-20",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "",
      "data": [
        {
          "txt": "Eiko Lifesciences Ltd has announced <strong>2:3</strong> rights issue, ex-date: 07 Jul 23",
          "dt": "2023-07-07",
          "middle_text": "Rights Issue"
        }
      ]
    }
  ]
}

News and Views

No Recent News for the Company

View All News